Apr 14, 2020 7:35am EDT Intensity Therapeutics Signs Clinical Collaboration Agreement with Bristol Myers Squibb for Advanced Solid Tumors
Mar 30, 2020 7:35am EDT Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda®
Nov 07, 2019 7:35am EST Data From Intensity Therapeutics’ Phase 1/2 Study of INT230-6 Highlight Prolonged Disease Control, Abscopal Effects and Immune Response Activity in Patients With Advanced Solid Tumors
Oct 31, 2019 7:35am EDT Intensity Therapeutics Treats First Patient with Combination of INT230-6 and Merck’s Keytruda®
Oct 22, 2019 7:35am EDT Intensity Therapeutics’ Intratumoral INT230-6 Tumor Regression and Immune Response Activity Data Selected for Oral Presentation at SITC 2019 Conference
Jul 17, 2019 8:27am EDT Intensity Therapeutics' INT230-6 Induces Immune Activation by Intratumoral Delivery as Reported in the Peer-Reviewed Journal OncoImmunology
Jun 01, 2019 7:35am EDT Intensity Therapeutics Presents Positive Preliminary Phase 1/2 Results for Intratumoral Injection of INT230-6 at ASCO 2019
May 16, 2019 7:35am EDT Intensity Therapeutics to Present Data on Safety, Tumor Regression and Immune Activation of INT230-6 at ASCO 2019
